Stockscreener 앱 받기
2.17
10.70%
-0.26
시간 외 거래:
2.22
0.05
+2.30%
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Truist Securities reiterates Buy rating on Caribou Biosciences stock By Investing.com - Investing.com South Africa
Assessing Caribou Biosciences (CRBU) Valuation After Early CB-011 CAR-T Data and Pipeline Progress - Yahoo Finance
Traders Purchase Large Volume of Caribou Biosciences Call Options (NASDAQ:CRBU) - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Given New $8.00 Price Target at Citigroup - MarketBeat
Truist Securities reiterates Buy rating on Caribou Biosciences stock - Investing.com
Published on: 2025-11-04 03:55:22 - newser.com
How to build a custom watchlist for Caribou Biosciences Inc.Bear Alert & AI Powered Buy/Sell Recommendations - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthMarket Performance Summary & Risk Managed Trade Strategies - newser.com
Analyzing Caribou Biosciences Inc. with multi timeframe chartsWatch List & Reliable Price Breakout Alerts - newser.com
Comparing Caribou Biosciences Inc. in custom built stock radarsQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
What machine learning models say about Caribou Biosciences Inc.Global Markets & Risk Adjusted Swing Trade Ideas - newser.com
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - Investing News Network
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - Investing News Network
Is Caribou Biosciences Inc. stock a contrarian buy2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
Caribou Bio leaps on early data for vispa-cel - The Pharma Letter
CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus
Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com
Caribou Says Potential Non-Hodgkin Lymphoma Therapy Shows High Overall Response; Shares Rise Pre-Bell - MarketScreener
Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedSwing Trade & High Conviction Investment Ideas - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update - Stock Titan
1.45%
0.86%
자본화:
|
볼륨(24시간):